S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)

Qualigen Therapeutics Stock Forecast, Price & News

+0.05 (+5.00%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
818,761 shs
Average Volume
907,030 shs
Market Capitalization
$30.88 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive QLGN News and Ratings via Email

Sign-up to receive the latest news and ratings for Qualigen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Qualigen Therapeutics logo

About Qualigen Therapeutics

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Los Angeles, CA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
($1.13) per share


Net Income
$-1.67 million
Pretax Margin




Free Float
Market Cap
$30.88 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.70 out of 5 stars

Medical Sector

947th out of 1,405 stocks

Pharmaceutical Preparations Industry

462nd out of 678 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Qualigen Therapeutics (NASDAQ:QLGN) Frequently Asked Questions

Is Qualigen Therapeutics a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qualigen Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Qualigen Therapeutics stock.
View analyst ratings for Qualigen Therapeutics
or view top-rated stocks.

Are investors shorting Qualigen Therapeutics?

Qualigen Therapeutics saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 2,410,000 shares, an increase of 33.9% from the December 15th total of 1,800,000 shares. Based on an average trading volume of 8,480,000 shares, the short-interest ratio is presently 0.3 days. Currently, 9.3% of the company's stock are short sold.
View Qualigen Therapeutics' Short Interest

When is Qualigen Therapeutics' next earnings date?

Qualigen Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, February 21st 2022.
View our earnings forecast for Qualigen Therapeutics

How were Qualigen Therapeutics' earnings last quarter?

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced its quarterly earnings results on Monday, November, 15th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.20) by $0.10. The company earned $1.16 million during the quarter, compared to the consensus estimate of $1.50 million.
View Qualigen Therapeutics' earnings history

What price target have analysts set for QLGN?

1 brokers have issued twelve-month price targets for Qualigen Therapeutics' shares. Their forecasts range from $6.50 to $6.50. On average, they expect Qualigen Therapeutics' stock price to reach $6.50 in the next year. This suggests a possible upside of 519.0% from the stock's current price.
View analysts' price targets for Qualigen Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Qualigen Therapeutics' key executives?

Qualigen Therapeutics' management team includes the following people:
  • Michael S. Poirier, Chairman & Chief Executive Officer
  • Amy Broidrick, President, Director & Chief Strategy Officer (LinkedIn Profile)
  • Shishir K. Sinha, Chief Operating Officer, Secretary & VP
  • Christopher L. Lotz, Chief Financial Officer & Vice President
  • Wajdi Abdul-Ahad, Chief Scientific Officer & Vice President-R&D

What other stocks do shareholders of Qualigen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Qualigen Therapeutics investors own include iBio (IBIO), Boeing (BA), Sorrento Therapeutics (SRNE), T2 Biosystems (TTOO), NIO (NIO), NVIDIA (NVDA), Riot Blockchain (RIOT), Vaxart (VXRT), Boxlight (BOXL) and Enphase Energy (ENPH).

What is Qualigen Therapeutics' stock symbol?

Qualigen Therapeutics trades on the NASDAQ under the ticker symbol "QLGN."

How do I buy shares of Qualigen Therapeutics?

Shares of QLGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Qualigen Therapeutics' stock price today?

One share of QLGN stock can currently be purchased for approximately $1.05.

How much money does Qualigen Therapeutics make?

Qualigen Therapeutics has a market capitalization of $30.88 million.

How many employees does Qualigen Therapeutics have?

Qualigen Therapeutics employs 36 workers across the globe.

What is Qualigen Therapeutics' official website?

The official website for Qualigen Therapeutics is www.qualigeninc.com.

Where are Qualigen Therapeutics' headquarters?

Qualigen Therapeutics is headquartered at 2042 Corte Del Nogal, Carlsbad CA, 92011.

How can I contact Qualigen Therapeutics?

Qualigen Therapeutics' mailing address is 2042 Corte Del Nogal, Carlsbad CA, 92011. The company can be reached via phone at (310) 203-1000 or via email at [email protected].

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.